Prof Hang Quach
Honorary Clinical Professor
Department of Medicine
567 Scholarly works
3 Projects
HIGHLIGHTS
2026
Journal article
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO
DOI: 10.1038/s41408-025-01436-02026
Journal article
Preventing infections after CD19-directed chimeric antigen receptor T-cell therapies for lymphoma: a consensus practice statement.
DOI: 10.1111/imj.706442026
Journal article
Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.
DOI: 10.1111/bjh.708512026
Journal article
MM-754: Safety and Reliability of Isatuximab Subcutaneous On-Body Injector: Results Across the Phase 3 IRAKLIA, Phase 2 IZALCO, and Phase 1b TCD15484 Trials
DOI: 10.1016/s2152-2650(26)02923-x2026
Journal article
MM-569: Mezigdomide, Carfilzomib, and Dexamethasone vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Results From the Phase 3 SUCCESSOR-2 Trial
DOI: 10.1016/s2152-2650(26)02893-42026
Journal article
Translocation t(11;14) and BCL2-inhibition in multiple myeloma
DOI: 10.3324/haematol.2025.2891472018
Research grants (other domestic)
Novel Immunotherapy Approach for Rescuing Inadequate Responses and Resistance to Treatment for Patients With Multiple Myeloma
RECENT SCHOLARLY WORKS
2026
Journal article
MM-780: Updated Results From the Phase 2 IZALCO Study: Efficacy and Safety of Isatuximab Subcutaneous Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
DOI: 10.1016/s2152-2650(26)02930-72026
Journal article
Characterising Diagnostic Delay in Cardiac Amyloidosis: An Exploratory Study of Factors Impacting Time to Diagnosis
DOI: 10.1016/j.hlc.2026.07.2742026
Journal article
POSTER: MM-569: Mezigdomide, Carfilzomib, and Dexamethasone vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Results From the Phase 3 SUCCESSOR-2 Trial
DOI: 10.1016/s2152-2650(26)01327-32026
Journal article
Prevalence of Abnormal Free Light Chain Assessment in ATTR Amyloidosis and Impact of Reclassification With the revised iSTOPMM Criteria for Light-Chain Monoclonal Gammopathy
DOI: 10.1016/j.hlc.2026.07.343
RECENT PROJECTS
2013
Research Grant
Targeting GRP-78 as a Means to Overcome Drug Resistance and as a Therapeutic Modaliaty Against Multiple Myeloma
2014
Research Grant
Targeting GRP-78 as a Means to Overcome Drug Resistance and as a Therapeutic Modaliaty Against Multiple Myeloma